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1
PROBLEM IDENTIFICATION AND
DESCRIPTION OF NEED
• There are several buprenorphine providers at EMMC’s Center for Family Medicine serving 
the greater Bangor region, an area of substantial opiate use
• Among the patient population of outpatient buprenorphine users, both locally and nationally, 
there are high rates of relapse (32%) 1
• In order to decrease relapse rates, it is imperative to conduct a baseline review of the current 
buprenorphine population to identify specific types of patients who are at higher risk of 
relapse
• By understanding the barriers to recovery, one can apply an intervention to the current 
program, targeting this local demographic more effectively 
• Future researchers can also use this baseline data as a control group, comparing the 
intervention to the current treatment model (medication, individual therapy, group therapy)
2
PUBLIC HEALTH COST OF OPIATES IN MAINE
• Deadly Crisis
• Deaths from heroin overdoses increased from 7 in 
2010 to 57 last year (2/3 between ages 20-40) 2
• Overdose deaths involving prescription drugs (e.g. 
methadone, oxycodone, and benzodiazepines) 
tripled from 51 in 2000 to 161 in 2010 3
• 95% of overdose deaths in Maine involved 
prescription drugs in 2010 3
• High Rehab Demand
• As of 2012, prescription opioids are the second most 
common substance for which treatment is sought, 
just behind alcohol 3
• 11,518 individuals sought rehab in Maine - 37.19% 
reported opioids as primary substance 4
• Ballooning Costs
• Estimated cost of substance abuse in Maine is $1.18 
billion, $888 for each Maine resident (crime, deaths, 
and medical care) 4
• Availability Increasing
• Heroin is more available, purity levels are 
increased, street prices have dropped resulting in 
dramatic increase in heroin addiction across the 
nation 5
• Burden on Crime Enforcement
• In 2012, heroin accounted for 8 percent of the 
caseload for Maine’s Drug Crimes Task Force; last 
year, it jumped to 32 percent 2
• Prices Dropping 
• Today in Maine, a single tablet of oxycodone often 
costs $50; addicts can find a single-dose packet of 
heroin for as little as $10 2
3
METHODOLOGY AND INTERVENTION
• Goal
• Develop a descriptive summary of current CFM buprenorphine users to understand the 
barriers to recovery in the greater Bangor area
• Methodology
• Retrospective chart review of all 
buprenorphine patients who have filled out 
both the Recovery Rating Scale and Opiate 
Craving Survey (n = 32) within the last year 
(July 2014-July 2015)
• Summarize key demographic information
• Report average scores on Recovery Rating 
Scale and Opiate Craving Survey
• Trend those patients who have filled out >2  
Opiate Craving Surveys
• Conduct interviews with community experts 
and patients on buprenorphine use
• Intervention 
• Presentation of data to the Social Workers and 
buprenorphine providers at EMMC’s CFM
• Share suggestions for program interventions 
based on identified barriers to recovery and 
community/patient perspectives 
• Compile baseline data into excel format for 
future data manipulation and to allow for use 
as a control group in future studies
• i.e. comparing future intervention to the 
current treatment model
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COMMUNITY PERSPECTIVE
Matt Nutt, LCSW – Opiate Addiction Counselor
Center for Family Medicine, Bangor, ME
• Public Health Concerns
• “Opiate dependence, when untreated, can result in overdose, 
medical complications, lack of healthcare coverage, lack of 
medical /dental care management, decrease in self-worth, 
decrease population in the workforce, […] and increased burden 
on public welfare resources.”
• Treatment to Fight Crime
• “Many long term users, dependent, eventually end up out of the 
workforce and in trouble […]. Opioid based replacement 
treatment are shown to decrease crime rates where treatment is 
available.”
• Identifying Comorbid Conditions
• “[…] there is a higher incidence of Hep C/HIV in the IV using 
community. When I was working at Acadia’s Narcotic Treatment 
Program, we had a 50% Hep C positive rate with a clinic treatment 
caseload of approximately 700 clients (mid to late 
2000s). Untreated Hep C/HIV often leads to very costly treatment 
later.” I believe screening these individuals and treating them 
during visits could drastically decrease costs and increase 
recovery rates.
Jessica Bloom-Foster, MD – Buprenorphine Provider
Center for Family Medicine, Bangor, ME
• Current Relapse Rates at CFM
• “I initially looked at 31 newly enrolled patients in the 
buprenorphine treatment program from January to June 
of 2014 and followed their charts to see who met 
definition of relapse. What we found mimicked the 
general population of buprenorphine users in that 32% 
met criteria for relapse. 
• Intervention Ideas
• “Based on anecdotal evidence in our buprenorphine 
population, I think there is room for a study on the role of 
mindfulness in recovery.  I envision the providers hosting 
a brief educational session on mindfulness at first intake 
and providing patients with audio files to practice their 
mindfulness tools once a day.”
• A Role for Providers
• “We hope to ultimately show that primary care docs can 
teach meaningful tools like mindfulness to patients in 
recovery programs and that these tools can make a 
substantial impact on their recovery time.”
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COMMUNITY PERSPECTIVE
Paula Codrington, LCSW – Opiate Addiction Counselor
Center for Family Medicine, Bangor, ME
• Psychological Hurdles
• “Addicts in recovery will take a few steps forward and then 
one back - relapse is part of the process so it should be 
considered a challenge not a failure”
• “Often people will get stuck and use the idea that they failed 
as the reason to keep using and not keep trying to take steps 
forward”
• “Black and white thinking (all or nothing perspective) makes 
it more difficult to maintain a path towards recovery”
• Importance of Self Awareness 
• “If you are not aware of what is going on in your head and 
heart and your patterns you can’t make change, and without 
being aware of the patterns, you can’t get past the hurdles to 
recovery” 
Anonymous Patient on Buprenorphine
Center for Family Medicine, Bangor, ME
• On Challenges
• “Other’s people influence [is the hardest part].  My neighbor 
asked me to help her shoot up heroin and it brought me right 
back to the feelings I would have before I used.  The sweats, 
anxiety…”
• On Coping Skills
• “I think of my family, husband, animals.  I try to keep busy. I used 
to be really sick and that is why I used.  I am feeling better health 
wise now that I am on [buprenorphine] so I don’t feel the need to 
use. [Also] being around others, having a support system is 
important.  I have learned more to stay away from negative 
people, like my neighbor.  It’s important to change social 
situations.”
• On Group Therapy
• “Group is good to learn [coping] skills. Group makes me feel 
better and I was anxious about that because I have bad anxiety 
and didn’t think I would like group.  Music meditation, we did that 
one, and I liked that.  Music is important to me.  Doing crafts or 
coloring which we do sometimes is good to help relieve stress, 
but it doesn’t [always] last.  It’s like a band aid.”  
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RESULTSPatient Demographics
• Sex of Patient (n=32)
• Male = 7 (22%)
• Female= 25 (78%)
• Pregnant = 21 (84%)
• Not pregnant = 4 (16%)
• Average age = 29.56 (n= 32)
• Age at 1st opiate use = 19.48 
(n=31)
• Comorbid Mental Health Dx (n=32)
• No =  7 (22%)
• Yes = 25 (78%)
• Multiple = 17 (68%)
• Average ACE Score = 5.85 (n=15)
• Previous Recovery Attempts (n=32)
• No = 13 (41%)
• Yes = 19 (59%)
• Key: Pink = Barriers to Recovery
Average Recovery Rating Scores
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RESULTS
Average Opiate Craving Scores
Scale Average Max %
RRS 1 23.34 35 67%
RRS 2 27.31 35 78%
RRS 3 18.46 20 92%
OCS 7.72 25 31%
Total Average Scores Per Scale
Opiate Craving Trends in Patients Who Completed >2 Forms (n = 6)
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Evidence of Program Success
• 3 patients with complete decreased 
craving scores (purple stars) 
• On average, low craving scores for 
patients on medication (pink)
• Very high RRS 3 % (orange)
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EVALUATION OF EFFECTIVENESS AND 
LIMITATIONS
• Limitations
• Due to the relatively recent distribution of the Opiate Craving Scale, 
the retrospective chart review yielded a small sample size with a 
large standard deviation across all measures
• In order to find any significance in outcomes of treatment, providers will 
likely need to greatly increase the patient population to include all ~ 200 
buprenorphine users in the practice
• Our evaluation relied on self reported data from a questionnaire, 
making it difficult to validate patient responses
• Poor self-esteem, a low level of education, and legal problems are 
common in opiate users and interfere with self-reporting 6
• Corroboration of the data with a second questionnaire, or variations on 
the same questions, may help increase validity and assess reliability
• The time interval between initial intake and survey distribution was 
not standardized and often not recorded
• Future studies need to standardize specific time stamps for data collection 
in order to yield significance – analyzing points in time will allow for 
better trending and more useful data analysis
• Effectiveness
• Our first aim was to 
summarize the data set - in 
this regard we succeeded
• Given the obstacles we 
encountered with data 
integrity, both the LICSWs 
and providers were pleased 
with our findings and will use 
our recommendations for 
future projects 
• The information compiled for 
future data manipulation was 
organized in excel and 
distributed to the team (see 
attached)
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RECOMMENDATIONS
Barriers to Recovery
• Females make up 78% of the patient population, 84% of whom were pregnant at intake
• Social stigma, guilt and shame of ongoing drug addiction during pregnancy may pressure the woman into attempting to quit using 
opiates on her own or hiding the problem until delivery 6
• The partner’s continued use of opiates can be an insurmountable problem because the woman may be caught in between the need 
for emotional/financial support with the continued temptation to relapse 6
• Treatment compliance and pregnancy outcomes are improved when addiction and obstetrical care are delivered at the same 
location 6
• Recommendation: Key in on these considerations while treating pregnant women in order to decrease relapse rates
• 78% of patients had a comorbid mental illness, and of those, 68% had a diagnosis of > 2 mental illnesses
• Psychiatric disorders are associated with increased physical symptoms such as pain and are associated with increased opioid use 7
• Recommendation: Imperative for providers and social workers to focus on treating mental health concurrently 
• Average scores for RRS1 (67%) and RRS2 (78%) could be improved across patient population
• On RRS 1, particularly low scores included answers to questions on stress management, daily physical activity, healthy eating, sleep 
hygiene, and social support improvement
• On RRS 2, particularly low scores included answers to questions on triggers and healthy coping skills
• Recommendation: Future interventions should include a focus on stress management, physical activity, healthy eating, sleep 
hygiene, social support, triggers and coping skills 
• e.g. a mindfulness program like the one suggested by Dr. Bloom Foster could be one key step toward decreasing relapse rates
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RECOMMENDATIONS
Evidence of Success with Current Program
• Very high patient satisfaction with therapy as measured by RRS3 (92%) 
• Overall low average on self-reported Opiate Craving Surveys (31%)
• Recommendation: Continue to provide therapy in combination with buprenorphine as much as possible for the best 
opportunity at a successful recovery
Additional Ideas and Recommendations for Future Investigation
• Standardize the intake process for all patients receiving buprenorphine, including specific times throughout the treatment at
which patients receive the RRS and OCS questionnaires
• Per Matthew Nutt’s suggestion, investigate the rates of HCV and HIV comorbidities in order to understand how these 
patients can be better screened and treated
• Looking at the small sample size of trending OCS responses (patients 25, 38, 48, 57, 59, 76), identify what factors make 
certain patients more successful via correlation with their RRS and demographic data
• Once local barriers to recovery are fully understood, one could project how well a patient will do in treatment and how 
likely he or she is to relapse
• Focus investigations on those with previous recovery attempts (59%) and ultimately failed to understand what may have 
occurred and individualize treatment based on those prior obstacles
• Per Paula Codrington’s suggestion, in each patient encounter, focus on psychological hurdles such as all-or-nothing thinking 
to help patients better understand the progression of recovery
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